Sutro Biopharma (STRO) Gains from Sales and Divestitures (2018 - 2025)

Sutro Biopharma has disclosed Gains from Sales and Divestitures across 8 years of filings, most recently posting $252107.0 for Q4 2025.

• Gains from Sales and Divestitures for Q4 2025 came in at $252107.0, down 85.13% year-over-year; the trailing twelve-month figure through Dec 2025 was $252107.0 (down 85.13% YoY), and the FY2025 annual result was $252107.0, down 85.13% from the prior year.
• Gains from Sales and Divestitures came in at $252107.0 for Q4 2025 at Sutro Biopharma, down from $2.3 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $2.3 million in Q3 2025 to a low of $147349.0 in Q1 2021.
• The 5-year median for Gains from Sales and Divestitures is $849019.0 (2023), against an average of $936361.2.
• Across the five-year window, Gains from Sales and Divestitures surged 265.86% in 2021 and plunged 85.13% in 2025, its largest moves.
• Sutro Biopharma's Gains from Sales and Divestitures stood at $238724.0 in 2021, then surged by 159.99% to $620647.0 in 2022, then surged by 86.2% to $1.2 million in 2023, then surged by 46.68% to $1.7 million in 2024, then slumped by 85.13% to $252107.0 in 2025.
• The last three Gains from Sales and Divestitures figures came in at $252107.0 (Q4 2025), $2.3 million (Q3 2025), and $2.0 million (Q2 2025), per Business Quant data.